Alexion Pharmaceuticals is a solid company that is the subject of acquisition rumors and Amicus Therapeutics has a key drug off to a strong start.
The treatment, fosmetpantotenate, fails to meet its primary endpoint when compared to a control group being treated with a placebo, the company says.
Teva says patients taking Ajovy experienced a significant reduction in migraine days compared to those receiving placebos.
I dub Resonant and Chiasma as 'busted IPOs'.
In its rejection of golodirsen, Sarepta's second treatment for Duchenne muscular dystrophy, the FDA cites concerns over infection risk 'related to intravenous infusion ports and renal toxicity,' the company says.
There has been an EpiPen shortage in the U.S., Europe and Canada, thanks to manufacturing delays at Pfizer.
Allergan is said to be discussing paying $5 million while Endo is close to an agreement to pay $10 million, according to a report.
Amarin's stock jumped after SVB Leerink upped its rating on the biotech's stock to outperform, saying a recent double-digit decline offers a buying opportunity.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.